Incidence of muscle symptoms in placebo arm among statin-intolerant patients: a systematic review with meta-analysis

References

• Mach F, Baigent C, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi: 10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Mihaylova, Borislava,Emberson, Jonathan ,and Blackwel et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590.
   PubMed Web of Science ®Google Scholar
• Chou R, Dana T, Blazina I, et al. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316(19):2008–2024. doi: 10.1001/jama.2015.15629
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Saeed B, Wright E, Evans M, et al. PS1-45: prevalence of statin intolerance in a high risk cohort and management strategies in contemporary cardiology. Clin Med Res. 2013;11(3):136–136. doi: 10.3121/cmr.2013.1176.ps1-45
   Google Scholar
• Reith C, Baigent C, Blackwell L, et al. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832–845. doi: 10.1016/S0140-6736(22)01545-8
   PubMed Web of Science ®Google Scholar
• Warden BA, Guyton JR, Kovacs AC, et al. Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17(1):19–39. doi: 10.1016/j.jacl.2022.09.001
   PubMed Web of Science ®Google Scholar
• Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;19:1–16.
   Google Scholar
• Parhofer K, Anastassopoulou A, Calver H, et al. Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany (2017 to 2020). J Clin Med. 2023;12(2):705. doi: 10.3390/jcm12020705
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015;14(6):935–955. doi: 10.1517/14740338.2015.1039980
   PubMed Web of Science ®Google Scholar
• Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16(4):361–375. doi: 10.1016/j.jacl.2022.05.068
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management. European Heart Journal. 2015;36(17):1012–1022. doi: 10.1093/eurheartj/ehv043
   PubMed Web of Science ®Google Scholar
• Penson PE, Mancini GBJ, Toth PP, et al. Introducing the ‘drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018;9(6):1023–1033. doi: 10.1002/jcsm.12344
   PubMed Web of Science ®Google Scholar
• Penson PE, Banach M. Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations. Eur Heart J. 2021;42(47):4787–4788. doi: 10.1093/eurheartj/ehab358
   PubMed Web of Science ®Google Scholar
• Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e158. doi: 10.1161/ATV.0000000000000073
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Hoy D, Brooks P, Woolf A, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65(9):934–939. doi: 10.1016/j.jclinepi.2011.11.014
   PubMed Web of Science ®Google Scholar
• Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi: 10.1136/bmj.315.7109.629
   PubMed Web of Science ®Google Scholar
• Barendregt JJ, Doi SA, Lee YY, et al. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67:974–978. doi: 10.1136/jech-2013-203104
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188. doi: 10.1016/0197-2456(86)90046-2
   PubMedGoogle Scholar
• Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758–769. doi: 10.1016/j.jacl.2015.08.006
   PubMed Web of Science ®Google Scholar
• Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015 May;9(3):295–304. doi: 10.1016/j.jacl.2015.03.003
   PubMed Web of Science ®Google Scholar
• Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019 Apr 2;8(7):e011662. doi: 10.1161/JAHA.118.011662
   PubMed Web of Science ®Google Scholar
• Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–1590. doi: 10.1001/jama.2016.3608
   PubMed Web of Science ®Google Scholar
• Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023 Apr 13;388(15):1353–1364. doi: 10.1056/NEJMoa2215024
   PubMed Web of Science ®Google Scholar
• Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33(9):1142–1149. doi: 10.1093/eurheartj/ehs023
   PubMed Web of Science ®Google Scholar
• Kennedy SP, Barnas GP, Schmidt MJ, et al. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. J Clin Lipidol. 2011;5(4):308–315. doi: 10.1016/j.jacl.2011.03.454
   PubMed Web of Science ®Google Scholar
• Taylor BA, Lorson L, White CM, et al. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238(2):329–335. doi: 10.1016/j.atherosclerosis.2014.12.016
   PubMed Web of Science ®Google Scholar
• Riaz H, Khan AR, Khan MS, et al. Meta-analysis of placebo-controlled randomized controlled trials on the prevalence of statin intolerance. Am J Cardiol. 2017 Sep 1;120(5):774–781. doi: 10.1016/j.amjcard.2017.05.046
   PubMed Web of Science ®Google Scholar
• v GH, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials curriculum in cardiology. Am Heart J. 2014;168(1):6–15. doi: 10.1016/j.ahj.2014.03.019
   PubMedGoogle Scholar
• Kaptchuk TJ, Stason WB, Davis RB, et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ. 2006;332(7538):391–397. doi: 10.1136/bmj.38726.603310.55
   PubMed Web of Science ®Google Scholar
• Diener H-C, Schorn C, Bingel U, et al. The importance of placebo in headache research. Cephalalgia. 2008;28(10):1003–1011. doi: 10.1111/j.1468-2982.2008.01660.x
   PubMed Web of Science ®Google Scholar
• Herrett E, Williamson E, Brack K, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021 Feb 24;372:n135. doi: 10.1136/bmj.n135
   PubMedGoogle Scholar
• Joy TR, Monjed A, Zou GY, et al. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med. 2014 Mar 4;160(5):301–310. doi: 10.7326/M13-1921
   PubMed Web of Science ®Google Scholar
• Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78(12):1210–1222. doi: 10.1016/j.jacc.2021.07.022
   PubMed Web of Science ®Google Scholar